Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

CDX2 is an amplified lineage-survival oncogene in colorectal cancer.

Salari K, Spulak ME, Cuff J, Forster AD, Giacomini CP, Huang S, Ko ME, Lin AY, van de Rijn M, Pollack JR.

Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):E3196-205. doi: 10.1073/pnas.1206004109. Epub 2012 Oct 29.

2.

The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review.

Olsen J, Espersen ML, Jess P, Kirkeby LT, Troelsen JT.

Surg Oncol. 2014 Sep;23(3):167-76. doi: 10.1016/j.suronc.2014.07.003. Epub 2014 Jul 17. Review.

PMID:
25126956
3.

The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.

Witek ME, Nielsen K, Walters R, Hyslop T, Palazzo J, Schulz S, Waldman SA.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8549-56.

4.

Cdx2 controls expression of the protocadherin Mucdhl, an inhibitor of growth and β-catenin activity in colon cancer cells.

Hinkel I, Duluc I, Martin E, Guenot D, Freund JN, Gross I.

Gastroenterology. 2012 Apr;142(4):875-885.e3. doi: 10.1053/j.gastro.2011.12.037. Epub 2011 Dec 24.

PMID:
22202456
5.

Cdx1 and Cdx2 function as tumor suppressors.

Hryniuk A, Grainger S, Savory JG, Lohnes D.

J Biol Chem. 2014 Nov 28;289(48):33343-54. doi: 10.1074/jbc.M114.583823. Epub 2014 Oct 15.

6.

CKIα ablation highlights a critical role for p53 in invasiveness control.

Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, Wiener Z, Alitalo K, Oren M, Pikarsky E, Ben-Neriah Y.

Nature. 2011 Feb 17;470(7334):409-13. doi: 10.1038/nature09673.

PMID:
21331045
7.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, Yamada T.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

PMID:
22155184
8.

Involvement of splicing factor-1 in beta-catenin/T-cell factor-4-mediated gene transactivation and pre-mRNA splicing.

Shitashige M, Naishiro Y, Idogawa M, Honda K, Ono M, Hirohashi S, Yamada T.

Gastroenterology. 2007 Mar;132(3):1039-54. Epub 2007 Jan 5.

PMID:
17383426
9.

Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression.

Brabletz T, Spaderna S, Kolb J, Hlubek F, Faller G, Bruns CJ, Jung A, Nentwich J, Duluc I, Domon-Dell C, Kirchner T, Freund JN.

Cancer Res. 2004 Oct 1;64(19):6973-7.

10.

CDX2 is mutated in a colorectal cancer with normal APC/beta-catenin signaling.

da Costa LT, He TC, Yu J, Sparks AB, Morin PJ, Polyak K, Laken S, Vogelstein B, Kinzler KW.

Oncogene. 1999 Sep 2;18(35):5010-4.

11.

The homeodomain transcription factor Cdx1 does not behave as an oncogene in normal mouse intestine.

Crissey MA, Guo RJ, Fogt F, Li H, Katz JP, Silberg DG, Suh ER, Lynch JP.

Neoplasia. 2008 Jan;10(1):8-19.

12.

Regulation of APC and AXIN2 expression by intestinal tumor suppressor CDX2 in colon cancer cells.

Olsen AK, Coskun M, Bzorek M, Kristensen MH, Danielsen ET, Jørgensen S, Olsen J, Engel U, Holck S, Troelsen JT.

Carcinogenesis. 2013 Jun;34(6):1361-9. doi: 10.1093/carcin/bgt037. Epub 2013 Feb 7.

13.
14.

Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome.

Sirnes S, Bruun J, Kolberg M, Kjenseth A, Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E, Rivedal E.

Int J Cancer. 2012 Aug 1;131(3):570-81. doi: 10.1002/ijc.26392. Epub 2011 Oct 20.

15.

Epigenetic silencing of HOPX promotes cancer progression in colorectal cancer.

Katoh H, Yamashita K, Waraya M, Margalit O, Ooki A, Tamaki H, Sakagami H, Kokubo K, Sidransky D, Watanabe M.

Neoplasia. 2012 Jul;14(7):559-71.

16.

Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells.

Bhat AA, Sharma A, Pope J, Krishnan M, Washington MK, Singh AB, Dhawan P.

PLoS One. 2012;7(6):e37174. doi: 10.1371/journal.pone.0037174. Epub 2012 Jun 15.

17.

Promoter methylation downregulates CDX2 expression in colorectal carcinomas.

Kawai H, Tomii K, Toyooka S, Yano M, Murakami M, Tsukuda K, Shimizu N.

Oncol Rep. 2005 Mar;13(3):547-51.

PMID:
15706431
18.

The microenvironment controls CDX2 homeobox gene expression in colorectal cancer cells.

Benahmed F, Gross I, Guenot D, Jehan F, Martin E, Domon-Dell C, Brabletz T, Kedinger M, Freund JN, Duluc I.

Am J Pathol. 2007 Feb;170(2):733-44.

19.

BCL9-2 promotes early stages of intestinal tumor progression.

Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W.

Gastroenterology. 2011 Oct;141(4):1359-70, 1370.e1-3. doi: 10.1053/j.gastro.2011.06.039. Epub 2011 Jun 23.

PMID:
21703997
20.

Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer.

Aguilera O, Fraga MF, Ballestar E, Paz MF, Herranz M, Espada J, García JM, Muñoz A, Esteller M, González-Sancho JM.

Oncogene. 2006 Jul 6;25(29):4116-21. Epub 2006 Feb 20.

PMID:
16491118
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk